Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lemaitre Vascular (NQ: LMAT )

108.98 +1.01 (+0.94%)
Streaming Delayed Price Updated: 2:55 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Lemaitre Vascular

< Previous 1 2 3 Next >
ResMed Is 80 And 80: Hits 80-Plus Relative Strength Rating After Rising 80% In A Year
ResMed also boasts a superb 96 EPS Rating out of 99, putting it in the top 4% of all companies for recent and long-term profit growth. 
Via Investor's Business Daily
Apple To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
In-Depth Examination Of 4 Analyst Recommendations For LeMaitre Vascular
Via Benzinga
This Synopsys Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Analyst Scoreboard: 4 Ratings For LeMaitre Vascular
Via Benzinga
Navigating 4 Analyst Ratings For LeMaitre Vascular
Via Benzinga
Recap: LeMaitre Vascular Q4 Earnings
Via Benzinga
Earnings Scheduled For February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
A Preview Of LeMaitre Vascular's Earnings
Via Benzinga
LMAT Stock Earnings: LeMaitre Vascular Beats EPS, Beats Revenue for Q2 2024
LMAT stock results show that LeMaitre Vascular beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Staar Surgical Stock Earns RS Rating Upgrade
On Thursday, lens maker Staar Surgical stock had its Relative Strength (RS) Rating upgraded to 87 from 77. 
Via Investor's Business Daily
Stryker Stock Sees RS Rating Treks Higher To 71
Stryker stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 63 to 71. 
Via Investor's Business Daily
Sell In May And Go Away? – April Dividend Income Report
The “Sell in May and Go Away” adage is wrong for most investors. 
Via Talk Markets
LMAT Stock Earnings: LeMaitre Vascular Beats EPS, Beats Revenue for Q1 2024
LMAT stock results show that LeMaitre Vascular beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Inspire Medical Systems Stock Sees IBD RS Rating Rise To 78
On Tuesday, Inspire Medical Systems stock earned an upgrade to its Relative Strength (RS) Rating, from 69 to 78. 
Via Investor's Business Daily
5 Analysts Have This to Say About LeMaitre Vascular
Via Benzinga
Recap: LeMaitre Vascular Q1 Earnings
Via Benzinga
Barrington Research Maintains Outperform Rating for LeMaitre Vascular: Here's What You Need To Know
Via Benzinga
Why LeMaitre Vascular Is A Market Leader In Core Segments: Oppenheimer Initiates With Outperform Rating
Oppenheimer has initiated coverage on LeMaitre Vascular Inc (NASDAQ: LMAT) with an Outperform rating and a  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
Via Benzinga
Looking for Dividend Growth? Buy This Little-Known Healthcare Stock
The healthcare company's dividend has soared in recent years. 
Via The Motley Fool
2 Healthcare Stocks That Could Help Make You a Fortune
These companies did well for shareholders over the last 10 years and have the potential to keep the growth going. 
Via The Motley Fool
Boston Scientific Stock Gets 81 RS Rating After Profit Pops 56% In Year
Boston Scientific stock rose from a 34.98 low on June 16, 2022, amid the bear market, to an all-time high 54.66 close on June 22 this year. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2023
Via Benzinga
Yum! Brands To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Thursday
Needham raised the price target for Extreme Networks, Inc. (NASDAQ: EXTR) from $30 to $35. Needham analyst Alex Henderson maintained a Buy rating. Extreme Networks shares fell 1.7% to $29.70 in... 
Via Benzinga
3 Micro-Cap Stocks to Buy Now for Gigantic Growth Potential
The smallest stocks have been trailing their larger counterparts. Here are three top micro-cap stocks to ride the asset class' resurgence. 
Via InvestorPlace
Beat the Dow Jones With This Unstoppable Dividend Stock
The wealth created by this medical devices company for its investors over the past decade far exceeds what the Dow Jones generated. 
Via The Motley Fool
Is This Healthcare Stock a Buy for Dividend Growth Investors?
This medical device maker has crushed the S&P 500 index in the past 10 years. 
Via The Motley Fool
Why Shares of LeMaitre Vascular Are Up Wednesday
LeMaitre announced first-quarter earnings and guidance numbers. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2023
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.